Here is the design of a clinical trial:

Official Title: Supervised Physical Activity in Subjects With Symptomatic Peripheral Arterial Disease. ARTPERfit Randomized Clinical Trial.

Included conditions:
- Peripheral Arterial Disease
- Arteriosclerosis

Study Armgroups:
- {'label': 'Walking intervention group', 'type': 'EXPERIMENTAL', 'description': 'It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.', 'interventionNames': ['Other: Walking intervention']}
- {'label': 'Strength intervention group', 'type': 'EXPERIMENTAL', 'description': 'The training program consists of performing a training program with resistance exercises for 36-72 weeks.', 'interventionNames': ['Other: Strength intervention']}
- {'label': 'Concurrent intervention group', 'type': 'EXPERIMENTAL', 'description': 'The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli.', 'interventionNames': ['Other: Concurrent intervention']}
- {'label': 'Control group', 'type': 'NO_INTERVENTION', 'description': 'It will receive standard advice consisting of the recommendation to perform aerobic exercise at the lower limbs level.'}

Interventions:
- {'type': 'OTHER', 'name': 'Walking intervention', 'description': 'It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.\n\nDepending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient.', 'armGroupLabels': ['Walking intervention group']}
- {'type': 'OTHER', 'name': 'Strength intervention', 'description': "The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.", 'armGroupLabels': ['Strength intervention group']}
- {'type': 'OTHER', 'name': 'Concurrent intervention', 'description': 'The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.', 'armGroupLabels': ['Concurrent intervention group']}

Primary Outcomes:
- {'measure': 'Pain-free walking distance', 'description': 'Pain-free walking distance using Treadmill based walking', 'timeFrame': '3 months from the start of the study'}
- {'measure': 'Pain-free walking distance', 'description': 'Pain-free walking distance using Treadmill based walking', 'timeFrame': '6 months from the start of the study'}
- {'measure': 'Pain-free walking distance', 'description': 'Pain-free walking distance using the 6-minute walk test distance', 'timeFrame': '3 months from the start of the study'}
- {'measure': 'Pain-free walking distance', 'description': 'Pain-free walking distance using the 6-minute walk test distance', 'timeFrame': '6 months from the start of the study'}
- {'measure': 'General functional state', 'description': 'General functional state using the Barthel questionnaire.', 'timeFrame': '3 months from the start of the study'}
- {'measure': 'General functional state', 'description': 'General functional state using the Barthel questionnaire.', 'timeFrame': '6 months from the start of the study'}
- {'measure': 'Perceived quality of life level', 'description': 'Perceived quality of life level', 'timeFrame': '3 months from the start of the study'}
- {'measure': 'Perceived quality of life level', 'description': 'Perceived quality of life level', 'timeFrame': '6 months from the start of the study'}
- {'measure': 'Ankle-Brachial Index (ABI)', 'description': 'To know if the proposed training programs improve the ankle-brachial index.', 'timeFrame': '3 months from the start of the study'}
- {'measure': 'Ankle-Brachial Index (ABI)', 'description': 'To know if the proposed training programs improve the ankle-brachial index.', 'timeFrame': '6 months from the start of the study'}

Please estimate the sample size based on the assumption: 
Alpha risk of 0.05, power of 80%, 20% rate of lost to follow-up, bilateral contrasts, and a correlation of 0.5 between baseline and final measurements.
Calculation of sample size
        A sample of 124 patients, 31 per group, is needed to detect a 155 m improvement in pain-free walking distance after the intervention, assuming that the SD of the improvement is also 155 m (primary outcome 1). This is similar to an increase of 159âs walking without pain, for an average speed of 3.5âkm/hour, as has been described previsouly.33 This calculation is comparable to any improvement as long as the SD is equal to or less than this improvement, and to comparisons between the control group and any of the other groups (correction for three comparisons using Bonferroni). This calculation is analogous for the rest of the result variables (Barthel, SF-12, VascQOL-6, ABI) as long as the difference observed between groups is equal to or greater than the common SD (primary outcome 2). The correlation between baseline and final measurement has been assumed to be 0.5. For comparisons between the treatment and control groups using the proportional version (proportion of patients improving in one group vs the other) the differences should be 50% improvement vs 15% or, equivalently, 35% vs 5%. In all calculations, a 20% rate of lost to follow-up, an alpha risk of 0.05, power of 80% and bilateral contrasts have been assumed.